You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Recommendations for the management of tyrosinaemia type 1
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, January 2013
|
| DOI | 10.1186/1750-1172-8-8 |
| Pubmed ID | |
| Authors |
Corinne de Laet, Carlo Dionisi-Vici, James V Leonard, Patrick McKiernan, Grant Mitchell, Lidia Monti, Hélène Ogier de Baulny, Guillem Pintos-Morell, Ute Spiekerkötter |
| Abstract |
The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 163 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 161 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 25 | 15% |
| Student > Bachelor | 25 | 15% |
| Other | 14 | 9% |
| Researcher | 14 | 9% |
| Student > Ph. D. Student | 11 | 7% |
| Other | 23 | 14% |
| Unknown | 51 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 10% |
| Biochemistry, Genetics and Molecular Biology | 15 | 9% |
| Agricultural and Biological Sciences | 13 | 8% |
| Engineering | 4 | 2% |
| Other | 10 | 6% |
| Unknown | 56 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2023.
All research outputs
#4,598,766
of 23,394,907 outputs
Outputs from Orphanet Journal of Rare Diseases
#621
of 2,689 outputs
Outputs of similar age
#49,008
of 285,761 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#24
of 98 outputs
Altmetric has tracked 23,394,907 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,689 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,761 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.